Journal

Genome Medicine

Publication Date

4-21-2021

Volume

13

Issue

1

First Page

56

Document Type

Open Access Publication

DOI

10.1186/s13073-021-00872-4

13073_2021_872_MOESM1_ESM.docx (19 kB)
This file contains the DNA and amino acid sequences of the polyepitope DNA vaccines created for this study.

13073_2021_872_MOESM2_ESM.xlsx (26 kB)
This file contains Supplementary Table S1 to S4. Table S1. List of HLA-A2-restricted epitopes included in the octamers for optimizing polyepitope DNA vaccine design; Table S2. Selective neoantigens identified in E0771 mouse breast cancer; Table S3. Neoantigens identified in mouse breast cancer cell line 4T1.2; and Table S4. Neoantigens identified in cancer patient GTB16.

13073_2021_872_MOESM3_ESM.pdf (1561 kB)
This file contains Supplementary Methods and Supplementary Figure S1 to S4. Figure S1. Expression of polyepitope constructs and the presentation of antigens. Figure S2. SLP vaccines generated neoepitope-specific CD4 T cell responses. Figure S3. Ubmut-4T1.2 Polyepitope neoantigen DNA vaccine inhibits 4T1.2 tumor growth in vivo. Figure S4. Both MT and WT Lrrc27 peptides bind well to H-2Db.

Share

COinS